临床和实验医学杂志2024,Vol.23Issue(15) :1594-1597.DOI:10.3969/j.issn.1671-4695.2024.15.008

多发性骨髓瘤外周血T淋巴细胞中TIGIT表达及临床意义

Expression of TIGIT in peripheral blood T lymphocytes of multiple myeloma and its clinical significance

缪英霞 王斌 高建强 李月圆 鲁桂华
临床和实验医学杂志2024,Vol.23Issue(15) :1594-1597.DOI:10.3969/j.issn.1671-4695.2024.15.008

多发性骨髓瘤外周血T淋巴细胞中TIGIT表达及临床意义

Expression of TIGIT in peripheral blood T lymphocytes of multiple myeloma and its clinical significance

缪英霞 1王斌 2高建强 3李月圆 4鲁桂华4
扫码查看

作者信息

  • 1. 海军军医大学第一附属医院 门诊医学科 上海 200433;海军军医大学第一附属医院 血液科 上海 200433
  • 2. 海军军医大学第一附属医院 肿瘤科 上海 200433
  • 3. 上海市静安区闸北中心医院核医学科 上海 200070
  • 4. 海军军医大学第一附属医院 门诊医学科 上海 200433
  • 折叠

摘要

目的 探讨多发性骨髓瘤外周血CD4+T淋巴细胞、CD8+T淋巴细胞中免疫受体酪氨酸抑制基序结构域(TIGIT)表达及临床意义.方法 前瞻性收集2022年3月至2023年7月入海军军医大学第一附属医院血液科住院治疗的初诊多发性骨髓瘤患者47例设为多发性骨髓瘤组,同时选取同期在该院体检中心体检健康的、与患者年龄匹配的志愿者40名设为对照组.流式细胞术检测两组研究对象的CD4+T、CD8+T淋巴细胞上TIGIT的表达,分析CD4+T淋巴细胞、CD8+T淋巴细胞上TIGIT表达水平与多发性骨髓瘤患者临床特征以及与临床检验指标的相关性.结果 多发性骨髓瘤组患者的CD4+T淋巴细胞、CD8+T淋巴细胞中TIGIT表达水平分别为(24.57±6.29)%、(42.87±5.71)%,均明显高于对照组[(9.18±3.06)%、(11.29±2.23)%],差异均有统计学意义(P<0.05).CD4+T淋巴细胞、CD8+T淋巴细胞上TIGIT表达水平与DS分期相关,且DS分期为Ⅲ期患者外周血中CD4+T淋巴细胞、CD8+T淋巴细胞上TIGIT表达水平明显高于Ⅰ~Ⅱ期患者,差异均有统计学意义(P<0.05),而与年龄、性别、ISS分期、有无肾损害、血磷、骨质破坏、尿本周蛋白无相关性,差异均无统计学意义(P>0.05).CD4+T淋巴细胞、CD8+T淋巴细胞上TIGIT表达水平与血红蛋白呈正相关(r=0.302、0.354,P<0.05),与β2微球蛋白呈负相关(r=-0.284、-0.296,P<0.05).结论 多发性骨髓瘤患者CD4+T淋巴细胞、CD8+T淋巴细胞上TIGIT表达水平升高,而且该表达与DS分期及血红蛋白、β2微球蛋白水平相关.

Abstract

Objective To investigate the expression of T-cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif do-main(TIGIT)in peripheral blood CD4+T lymphocytes and CD8+T lymphocytes in multiple myeloma and its clinical significance.Methods Forty-seven newly diagnosed multiple myeloma patients admitted to the Department of Hematology,the First Affiliated Hospital of Naval Medical University from March 2022 to July 2023 were prospectively collected as the multiple myeloma group.At the same time,40 age-matched volun-teers who were healthy in the physical examination center of our hospital during the same period were selected as the control group.The expression of TIGIT on CD4+T and CD8+T lymphocytes was detected by flow cytometry,and the correlation between the expression level of TIGIT on CD4+T lymphocytes and CD8+T lymphocytes and clinical characteristics of multiple myeloma patients and clinical test indicators was analyzed.Results The expression level of TIGIT in CD4+T lymphocytes and CD8+T lymphocytes in multiple myeloma group were(24.57±6.29)%,(42.87±5.71)%,which were higher than those in the control group[(9.18±3.06)%,(11.29±2.23)%],the differences were statistically signifi-cant(P<0.05).The level of TIGIT expression on CD4+T lymphocytes and CD8+T lymphocytes was correlated with DS stage,and the level of TIGIT expression on CD4+T lymphocytes and CD8+T lymphocytes in peripheral blood of patients with DS stage Ⅲ was significantly higher than that of patients with stage Ⅰ-Ⅱ,the differences were statistically significant(P<0.05).There were no statistically significant differences in age,sex,ISS stage,kidney damage,blood phosphorus,bone destruction and urinary weekly protein(P>0.05).The expression level of TIGIT on CD4+T lymphocytes and CD8+T lymphocytes was positively correlated with hemoglobin(r=0.302,0.354;P<0.05),and negatively cor-related with β2 microglobulin(r=-0.284,-0.296;P<0.05).Conclusion The expression of TIGIT in CD4+T lymphocytes and CD8+T lymphocytes is increased in patients with multiple myeloma,and the expression is closely related to DS stage,hemoglobin and β2 microglobulin.

关键词

多发性骨髓瘤/TIGIT/T淋巴细胞/血红蛋白/DS分期

Key words

Multiple myeloma/TIGIT/T lymphocytes/Hemoglobin/DS stage

引用本文复制引用

基金项目

上海市科委医学引导类科技支撑项目辅助项目(19411965600-1)

国家自然科学基金青年项目(82103768)

出版年

2024
临床和实验医学杂志
首都医科大学附属北京友谊医院

临床和实验医学杂志

CSTPCD
影响因子:1.504
ISSN:1671-4695
段落导航相关论文